,
,
Founder and Chief Executive Officer of Indivumed GmbH and Inostics GmbH in Hamburg. Hartmut Juhl studied medicine at the Hamburg-Eppendorf University Clinic from 1979 to 1986 and received his doctorate of medicine (“Dr.med.”) in 1989. From 1987 to 1992 he worked as a research associate and resident at the Hamburg-Eppendorf Surgical University Clinic. 1992 he moved to the Surgical Clinic of the Christians Albrecht University in Kiel, where he worked as a surgical oncologist and, in parallel, led a molecular oncology research group until 1998. He became a specialist in general surgery (“Facharzt”) in 1995 and obtained his habilitation in 1996. In 1999, he became Associate Professor at the Lombardi Cancer Center of Georgetown University in Washington, where he led a gastrointestinal cancer research group until 2002. In 2002, Hartmut Juhl became co-founder of Indivumed GmbH in Hamburg. Indivumed is focused on individualizing cancer therapy based on a highly standardized tumor tissue banks and comprehensive clinical data collection. Indivumed offers a broad range of specialized research services to pharmaceutical companies and actively performs a cancer biomarker development program. Indivumed and Hartmut Juhl have been awarded with the “Hamburg Foundation Prize” in the category of “Founders of new Businesses” in 2003, as well as the German Foundation Prize in the category of “Visionary” in 2005. In 2008, Indivumed GmbH and scientists from Johns Hopkins University, Baltimore/Maryland, founded the subsidiary Inostics GmbH which is specialized in detection of cancer-specific somatic DNA-changes. Hartmut Juhl holds an extraordinary professorship at the Medical Faculty of Hamburg University and is Adjunct Professor at the Lombardi Cancer Center of Georgetown University in Washington, D.C.
|
|
|